GeoVax Labs, Inc. (GOVX)
Market Cap | 8.37M |
Revenue (ttm) | n/a |
Net Income (ttm) | -27.78M |
Shares Out | 2.53M |
EPS (ttm) | -14.51 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 1,952,833 |
Open | 3.510 |
Previous Close | 3.280 |
Day's Range | 2.900 - 3.590 |
52-Week Range | 1.090 - 10.245 |
Beta | 2.78 |
Analysts | Strong Buy |
Price Target | 8.00 (+141.69%) |
Earnings Date | Aug 7, 2024 |
About GOVX
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM0... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for GOVX stock is "Strong Buy" and the 12-month stock price forecast is $8.0.
News
![](https://cdn.snapi.dev/images/v1/i/s/press19-2357064.jpg)
GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine
Presentation Made During the 24th Annual World Vaccine Congress ATLANTA, GA, April 04, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing...
![](https://cdn.snapi.dev/images/v1/f/x/conf20-2346191.jpg)
GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress
ATLANTA, GA, March 28, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious dise...
![](https://cdn.snapi.dev/images/v1/0/7/conf8-2319975.jpg)
GeoVax to Present at the 36th Annual Roth Conference
ATLANTA, GA, March 12, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious dis...
![](https://cdn.snapi.dev/images/v1/0/d/press6-2310855.jpg)
GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System
Manufacturing Process for Phase 3 and Commercial Production Being Developed for GeoVax MVA-Based Vaccines ATLANTA, GA, March 06, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: ...
![](https://cdn.snapi.dev/images/v1/i/g/press6-2302219.jpg)
GeoVax Reports 2023 Year-End Financial Results and Provides Business Update
Progress across the pipeline in multiple clinical trials, including Phase 2 program of GEO-CM04S1, next-generation Covid-19 vaccine, and multicenter Phase 1/2 study of Gedeptin ® , targeting advanced ...
![](https://cdn.snapi.dev/images/v1/f/l/conf12-2288535.jpg)
GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024
GeoVax to Host Conference Call at 4:30 PM ET ATLANTA, GA, Feb. 22, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immun...
![](https://cdn.snapi.dev/images/v1/z/v/conf14-2282137.jpg)
GeoVax to Present at the 2024 BIO CEO & Investor Conference
ATLANTA, GA, Feb. 19, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious disea...
![](https://cdn.snapi.dev/images/v1/z/3/press9-2273453.jpg)
GeoVax Announces Multiple Patent Issuances and Allowances
Intellectual Property Assets Strengthened for Cancer Immunotherapy Program and for Marburg Virus and HIV Vaccines
![](https://cdn.snapi.dev/images/v1/l/c/press6-2262044.jpg)
GeoVax Reports Positive Interim Data From Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster
Results Demonstrate Potential Protective Immunity Against Multiple SARS-CoV-2 Variants ATLANTA, GA, Feb. 06, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnolo...
![](https://cdn.snapi.dev/images/v1/b/m/press19-2248700.jpg)
GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement
ATLANTA, GA, Jan. 29, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious dise...
![](https://cdn.snapi.dev/images/v1/n/d/press9-2220304.jpg)
GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology
Strengthening GeoVax's Team Advancing Gedeptin® Clinical Program ATLANTA, GA, Jan. 08, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing ...
![](https://cdn.snapi.dev/images/v1/w/d/press3-2216462.jpg)
GeoVax Announces Gedeptin® Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients
Therapy Demonstrated Safety, Stabilization/Shrinkage of Treated Tumors Expanded Development for Monotherapy and Combination Therapy Anticipated ATLANTA, GA, Jan. 04, 2024 (GLOBE NEWSWIRE) -- via NewMe...
![](https://cdn.snapi.dev/images/v1/s/m/press2-2214717.jpg)
GeoVax Announces Issuance of Malaria Vaccine Patent
Patent Covers Multiple Component Vaccine for Both Prevention and Treatment ATLANTA, GA, Jan. 03, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company d...
![](https://cdn.snapi.dev/images/v1/s/m/conf9-2208967.jpg)
GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2024
ATLANTA, GA, Dec. 27, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious disea...
![](https://cdn.snapi.dev/images/v1/p/d/press12-2201892.jpg)
GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox
ATLANTA, GA, Dec. 19, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious disea...
![](https://cdn.snapi.dev/images/v1/u/1/press6-2178924.jpg)
GeoVax Hemorrhagic Fever Vaccine Data Presented at World Vaccine Congress
ATLANTA, GA, Nov. 30, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious disea...
![](https://cdn.snapi.dev/images/v1/d/x/press15-2175859.jpg)
GeoVax to Participate in Upcoming December Investor Events
ATLANTA, GA, Nov. 29, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious disea...
![](https://cdn.snapi.dev/images/v1/c/y/press8-2173878.jpg)
GeoVax COVID-19 Vaccine Clinical Data Presented at World Vaccine Congress
Presentation of Data from Phase 2 Open-Label Study of GEO-CM04S1 Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients ATLANTA, GA, Nov. 28...
![](https://cdn.snapi.dev/images/v1/q/w/press2-2156927.jpg)
Progress on GeoVax's Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023
Single-Dose Protection Demonstrated Against Multiple SARS-CoV-2 Variants ATLANTA, GA, Nov. 14, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company dev...
![](https://cdn.snapi.dev/images/v1/0/i/press17-2147950.jpg)
GeoVax Reports Third Quarter 2023 Financial Results and Provides Business Update
Significant Progress towards data milestones in Phase 2 Program of GEO-CM04S1, Next-generation COVID-19 vaccine Gedeptin ® clinical data from Phase 1/2 study presented at AACR-AHNS Head and Neck Cance...
![](https://cdn.snapi.dev/images/v1/x/v/press5-2127936.jpg)
GeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine
Designed to Protect Immunocompromised Patients Against Severe COVID-19 ATLANTA, GA, Oct. 30, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company deve...
![](https://cdn.snapi.dev/images/v1/k/z/press1-2119726.jpg)
GeoVax to Participate in Upcoming November Investor and Industry Events
ATLANTA, GA, Oct. 25, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious disea...
![](https://cdn.snapi.dev/images/v1/r/y/press2-2117331.jpg)
GeoVax Update: Clinical and Operational Progress Toward Transformative Opportunities
ATLANTA, GA, Oct. 24, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious disea...
![](https://cdn.snapi.dev/images/v1/v/b/press6-2094982.jpg)
GeoVax Receives Notice of Allowance for Marburg Vaccine Patent
ATLANTA, GA, Oct. 09, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious dise...
![](https://cdn.snapi.dev/images/v1/j/a/press20-2091397.jpg)
GeoVax Receives Notice of Allowance for HIV Vaccine Patent
ATLANTA, GA, Oct. 05, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious disea...